

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :  C07D 417/04, 333/38, 409/04, 413/04, 417/12, 417/14, 409/12, A61K 31/381, 31/426, A61P 43/00		A1	(11) International Publication Number: <b>WO 00/47578</b>  (43) International Publication Date: 17 August 2000 (17.08.00)
(21) International Application Number: PCT/US99/18065  (22) International Filing Date: 11 August 1999 (11.08.99)		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 09/247,062 9 February 1999 (09.02.99) US		Published With international search report.	
(71) Applicant: 3-DIMENSIONAL PHARMACEUTICALS, INC. [US/US]; Eagleview Corporate Center, Suite 104, 665 Stockton Drive, Exton, PA 19341 (US).			
(72) Inventors: ILLIG, Carl, R.; 25 Jonathan Drive, Phoenixville, PA 19460 (US). SUBASINGHE, Nalin, L.; 129 Longford Road, West Chester, PA 19380 (US). HOFFMAN, James, B.; 2425 Chestnut Avenue, Ardmore, PA 19003 (US). WILSON, Kenneth, J.; 137 Atherton Drive, Exton, PA 19341 (US). RUDOLPH, M., Jonathan; 3820 West Brandon Way, Doylestown, PA 18901 (US). MARUGÁN, Juan, José; 104 Coach Lane, Exton, PA 19341 (US).			
(74) Agents: GOLDSTEIN, Jorge, A. et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., Suite 600, 1100 New York Avenue, N.W., Washington, DC 20005-3934 (US).			

(54) Title: HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS



(57) Abstract

The present invention is directed to compounds of Formula (I) wherein X is O, S or NR<sup>7</sup> and R<sup>1</sup>-R<sup>7</sup>, Y and Z are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof. Also described are methods for preparing the compounds of Formula (I). The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, plasmin and urokinase. Certain of the compounds exhibit direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5

## HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS

10

*Field of the Invention*

The present invention relates to novel heteroaryl compounds that function as enzyme inhibitors, and particularly to a new class of non-peptidic inhibitors of proteolytic enzymes such as urokinase (uPa).

*Related Art*

15

Proteases are enzymes that cleave proteins at single, specific peptide bonds. Proteases can be classified into four generic classes: serine, thiol or cysteinyl, acid or aspartyl, and metalloproteases (Cuypers *et al.*, *J. Biol. Chem.* 257:7086 (1982)). Proteases are essential to a variety of biological activities, such as digestion, formation and dissolution of blood clots, reproduction and the immune reaction to foreign cells and organisms. Aberrant proteolysis is associated with a number of disease states in man and other mammals. The human neutrophil proteases, elastase and cathepsin G, have been implicated as contributing to disease states marked by tissue destruction. These disease states include emphysema, rheumatoid arthritis, corneal ulcers and glomerular nephritis.

20

25 (Barret, in *Enzyme Inhibitors as Drugs*, Sandler, ed., University Park Press, Baltimore, (1980)). Additional proteases such as plasmin, C-1 esterase, C-3 convertase, urokinase and tissue-type plasminogen activators, acrosin, and kallikreins play key roles in normal biological functions of mammals. In many

-2-

5 instances, it is beneficial to disrupt the function of one or more proteolytic enzymes in the course of therapeutically treating a mammal.

10 Serine proteases include such enzymes as elastase (human leukocyte), cathepsin G, plasmin, C-1 esterase, C-3 convertase, urokinase and tissue-type plasminogen activators, acrosin, chymotrypsin, trypsin, thrombin, factor Xa and kallikreins.

15 Human leukocyte elastase is released by polymorphonuclear leukocytes at sites of inflammation and thus is a contributing cause for a number of disease states. Cathepsin G is another human neutrophil serine protease. Compounds with the ability to inhibit the activity of these enzymes are expected to have an anti-inflammatory effect useful in the treatment of gout, rheumatoid arthritis and other inflammatory diseases, and in the treatment of emphysema. Chymotrypsin and trypsin are digestive enzymes. Inhibitors of these enzymes are useful in treating pancreatitis. Inhibitors of urokinase plasminogen activator are useful in treating excessive cell growth disease states, such as benign prostatic hypertrophy, 20 prostatic carcinoma and psoriasis.

25 Urokinase (urinary-type plasminogen activator or uPA; International Union of Biochemistry Classification Number: EC3.4.21.31) is a proteolytic enzyme which is highly specific for a single peptide bond in plasminogen. It is a multidomain serine protease, having a catalytic "B" chain (amino acids (aa) 144-411), and an amino-terminal fragment ("ATF", aa 1-143) consisting of a growth factor-like domain (4-43) and a Kringle domain (aa 47-135). The uPA Kringle domain appears to bind heparin, but not fibrin, lysine, or aminohexanoic acid. The growth factor-like domain bears some similarity to the structure of epidermal growth factor (EGF) and is thus also referred to as "EGF-like" domain. 30 The single chain pro-uPA is activated by plasmin, cleaving the chain into a two-chain active form that is stabilized by a disulfide bond.

35 Cleavage of the peptide bond in plasminogen by urokinase ("plasminogen activation") results in the formation of a potent general protease, plasmin. Many cell types use urokinase as a key initiator of plasmin-mediated proteolytic degradation or modification of extracellular support structures (e.g., the

-3-

5                   extracellular matrix (ECM) and the basement membrane (BM)). Cells exist, move, and interact with each other in tissues and organs within the physical framework provided by the ECM and BM. Movement of cells within the ECM or across the BM requires local proteolytic degradation or modification of these structures, allowing cells to "invade" into adjacent areas that were previously  
10                   unavailable.

Central to the ability of urokinase to mediate cellular migration and invasiveness is the existence of specific high affinity urokinase receptors (uPARs) which concentrate urokinase on the cell surface, leading to the generation of locally high plasmin concentrations between cells and ECM or BM (Blasi, F., *et al.*, *Cell Biol.* 104:801-804 (1987); Roldan, A.L., *et al.*, *EMBO J.* 9:467-74 (1990)). The binding interaction is apparently mediated by the EGF-like domain (Rabbani, S.A., *et al.*, *J. Biol. Chem.* 267:14151-56 (1992)). Cleavage of pro-uPA into active uPA is accelerated when pro-uPA and plasminogen are receptor-bound. Thus, plasmin activates pro-uPA, which in turn activates more plasmin by cleaving plasminogen. This positive feedback cycle is apparently limited to the receptor-based proteolysis on the cell surface, since a large excess of protease inhibitors is found in plasma, including  $\alpha_2$  antiplasmin, PAI-1 and PAI-2. High plasmin concentrations between invasive cells and ECM or BM are necessary in order to overcome inhibitory effect of these ubiquitous plasmin inhibitors. Thus, it is cell surface receptor-bound urokinase, and not simply free urokinase secreted by cells, which plays the predominant role in initiating cellular invasiveness.

Plasmin can activate or degrade extracellular proteins such as fibrinogen, fibronectin, and zymogens, including matrix metalloproteinases. Plasminogen activators thus can regulate extracellular proteolysis, fibrin clot lysis, tissue remodeling, developmental cell and smooth muscle cell migration, inflammation, and metastasis. Cellular invasiveness initiated by urokinase is central to a wide variety of normal and disease-state physiological processes (reviewed in Blasi, F., *et al.*, *J. Cell Biol.* 104:801-804 (1987); Danø, K., *et al.*, *Adv. Cancer Res.* 44:139-266 (1985); Littlefield, B.A., *Ann. N.Y. Acad. Sci.* 622:167-175 (1991); Saksela,

-4-

5 O., *Biochim. Biophys. Acta* 823:35-65 (1985); Testa, J.E., and Quigley, J.P.,  
Cancer Metast. Rev. 9:353-367 (1990)). Such processes include, but are not  
limited to, angiogenesis (neovascularization), bone restructuring, embryo  
implantation in the uterus, infiltration of immune cells into inflammatory sites,  
ovulation, spermatogenesis, tissue remodeling during wound repair, restenosis  
10 and organ differentiation, fibrosis, local invasion of tumors into adjacent areas,  
metastatic spread of tumor cells from primary to secondary sites, and tissue  
destruction in arthritis. Inhibitors of urokinase therefore have mechanism-based  
anti-angiogenic, anti-arthritis, anti-inflammatory, anti-restenotic, anti-invasive,  
anti-metastatic, anti-osteoporotic, anti-retinopathic (for angiogenesis-dependent  
15 retinopathies), contraceptive, and tumorstatic activities. Inhibitors of urokinase  
are useful agents in the treatment of a variety of disease states, including but not  
limited to, benign prostatic hypertrophy, prostatic carcinoma and psoriasis.

Beneficial effects of urokinase inhibitors have been reported using anti-urokinase monoclonal antibodies and certain other known urokinase inhibitors. For instance, anti-urokinase monoclonal antibodies have been reported to block tumor cell invasiveness *in vitro* (Hollas, W., *et al.*, *Cancer Res.* 51:3690-3695, (1991); Meissauer, A., *et al.*, *Exp. Cell Res.* 192:453-459 (1991)), tumor metastasis and invasion *in vivo* (Ossowski, L., *J. Cell Biol.* 107:2437-2445 (1988); Ossowski, L., *et al.*, *J. Cancer Res.* 51:274-81 (1991)), and angiogenesis *in vivo* (Jerdan, J. A., *et al.*, *J. Cell Biol.* 115[3 Pt 2]:402a (1991)). In addition, amiloride, a known urokinase inhibitor of only moderate potency, has been reported to inhibit tumor metastasis *in vivo* (Kellen, J.A., *et al.*, *Anticancer Res.* 8:1373-1376 (1988)) and angiogenesis/capillary network information *in vitro* (Alliegro, M.A., *et al.*, *J. Cell Biol.* 115[3 Pt 2]:402a (1991)).

30 Urokinase plays a significant role in vascular wound healing and arterial  
neointima formation after injury, most likely affecting cellular migration.  
Urokinase mediates plasmin proteolysis, which in turn promotes vascular wound-  
healing and associated neointima formation (Carmeliet *et al.*, *Circ. Res.* 81:829-  
839 (Nov. 1997), Lupu *et al.*, *Fibrinolysis* 10 Supp 2:33-35 (1996)). A viral  
35 serine proteinase inhibitor, SERP-1, has been employed to reduce plaque

5 formation after primary balloon angioplasty in rabbits. This activity has been attributed to the inhibition by SERP-1 of cellular proteinases, such as plasmin or urokinase (Lucas *et al.*, *Circulation* 94:2890-2900 (1996)).

10 A need continues for non-peptidic compounds that are potent and selective urokinase inhibitors, and which possess greater bioavailability and fewer side-effects than currently available urokinase inhibitors. Accordingly, new classes of potent urokinase inhibitors, characterized by potent inhibitory capacity and low toxicity, are potentially valuable therapeutic agents for a variety of conditions.

### *Summary of the Invention*

15 The present invention is broadly directed to the use of heteroaryl amidines, methylamidines and guanidines having Formula I (below) as protease inhibitors, preferably as urokinase inhibitors.

20 Compounds of the present invention exhibit anti-urokinase activity via direct, selective inhibition of urokinase, or are intermediates useful for forming compounds having such activity. Compounds of the present invention inhibit urokinase and are, therefore, useful anti-angiogenic, anti-arthritis, anti-inflammatory, anti-restenotic, anti-invasive, anti-metastatic, anti-osteoporotic, anti-retinopathic (for angiogenesis-dependent retinopathies), contraceptive, and tumoristatic treatment agents. For example, such treatment agents are useful in the treatment of a variety of disease states, including but not limited to, benign 25 prostatic hypertrophy, prostatic carcinoma, tumor metastasis and psoriasis.

Also provided are methods to inhibit extracellular proteolysis, methods to treat benign prostatic hypertrophy, prostatic carcinoma, tumor metastasis, psoriasis, and other conditions by administering the compound of Formula I.

30 A number of the heteroaryl compounds described herein are novel compounds. Therefore, the present invention is also directed to novel compounds of Formula I.

-6-

5


Further provided are pharmaceutical compositions comprising a compound of Formula *I* and one or more pharmaceutically acceptable carriers or diluents and said pharmaceutical compositions further comprising a thrombolytic agent such as tissue plasminogen activator and streptokinase.

10

Further provided are methods of synthesizing compounds of Formula *I*.

### *Detailed Description of the Preferred Embodiments*

The present invention is broadly directed to a method of inhibiting proteases, particularly serine proteases, by contacting a serine protease with a compound of the general Formula *I*:



15

or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein:

X is O, S or NR<sup>7</sup>, where R<sup>7</sup> is hydrogen, alkyl, aralkyl, hydroxy(C<sub>2-4</sub>)alkyl, or alkoxy(C<sub>2-4</sub>)alkyl;

Y is a direct covalent bond, CH<sub>2</sub> or NH;

20

Z is NR<sup>5</sup>R<sup>6</sup>, hydrogen or alkyl, provided that Y is NH whenever Z is hydrogen or alkyl;

R<sup>1</sup> is hydrogen, amino, hydroxy, halogen, cyano, C<sub>1-4</sub> alkyl or -CH<sub>2</sub>R, where R is hydroxy, amino or C<sub>1-3</sub> alkoxy;

R<sup>2</sup> and R<sup>3</sup> are independently:

25

- i. hydrogen;
- ii. halogen;
- iii. hydroxy;
- iv. nitro;
- v. cyano;

5                 vi.    amino, monoalkylamino, dialkylamino, monoarylarnino, diarylamino, monoalkylmonoarylarnino, monoaralkylarnino, diaralkylarnino, monoalkylmonoaralkylarnino, monoheterocyclearnino, diheterocyclearnino, monoalkylmonoheterocyclearnino, alkoxy carbonylarnino, aralkoxy carbonylarnino, aryloxy carbonylarnino, alkylsulfonylarnino, aralkylsulfonylarnino, aralkenylsulfonylarnino, arylsulfonylarnino, heteroaryl sulfonylarnino, di(aralkylsulfonyl)arnino, di(aralkenylsulfonyl)arnino, di(arylsulfonyl)arnino, or di-(heteroaryl sulfonyl)arnino, formylarnino, alkanoylarnino, alkenoylarnino, alkynoylarnino, aroylarnino, aralkanoylarnino, aralkenoylarnino, heteroaroylarnino, heteroaralkanoylarnino, H(S)CNH-, or thioacylarnino, wherein any of the aryl or heteroaryl containing groups can be optionally substituted on the aromatic ring and wherein any of the heterocycle containing groups can be optionally ring substituted;

10                 vii.    aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, acyl, aminoacyl, monoarylaminocarbonyl, diarylaminocarbonyl or monoalkylmonoarylaminocarbonyl;

15                 viii.   aminothiocarbonyl, monoalkylaminothiocarbonyl, dialkylaminothiocarbonyl, thioacyl or aminothioacyl;

20                 ix.    aminocarbonylarnino, mono- and dialkylaminocarbonylarnino, mono- and diarylaminocarbonylarnino, or mono- and diaralkylaminocarbonylarnino;

25                 x.    aminocarbonyloxy, mono- and dialkylaminocarbonyloxy, mono- and diarylaminocarbonyloxy, mono- and diaralkylaminocarbonyloxy;

               xi.    aminosulfonyl, mono- and dialkylaminosulfonyl, mono- and diarylaminosulfonyl, or mono- and diaralkylaminosulfonyl;

30                 xii.   alkoxy, or alkylthio, wherein the alkyl portion of each group may be optionally substituted,

               xiii.   aralkoxy, aryloxy, heteroaryloxy, aralkylthio, arylthio, or heteroarylthio, wherein the aryl portion of each group can be optionally substituted;

-8-

5           xiv. alkylsulfonyl, wherein the alkyl portion can be optionally substituted;

xv. aralkylsulfonyl, aralkenylsulfonyl, arylsulfonyl or heteroarylsulfonyl, wherein the aryl portion of each group can be optionally substituted;

10           xvi. alkenyl, or alkynyl;

xvii. optionally substituted aryl;

xviii. optionally substituted alkyl;

xix. optionally substituted aralkyl;


xx. optionally substituted heterocycle; or

15           xxi. optionally substituted cycloalkyl; and

R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently hydrogen, C<sub>1-4</sub> alkyl, aryl, hydroxyalkyl, aminoalkyl, monoalkylamino(C<sub>2-10</sub>)alkyl, dialkylamino(C<sub>2-10</sub>)alkyl, carboxyalkyl, cyano, amino, alkoxy, or hydroxy, or -CO<sub>2</sub>R<sup>w</sup>, where

R<sup>w</sup> is alkyl, cycloalkyl, phenyl, benzyl,

20



where R<sup>d</sup> and R<sup>e</sup> are independently hydrogen, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl or phenyl, R<sup>f</sup> is hydrogen, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl or phenyl, R<sup>g</sup> is hydrogen, C<sub>1-6</sub> alkyl, C<sub>2-6</sub> alkenyl or phenyl, and R<sup>h</sup> is aralkyl or C<sub>1-6</sub> alkyl.

25

The present invention is also directed to novel compounds of Formula I, where X, Y and R<sup>1</sup>-R<sup>6</sup> are as defined above;

provided that at least one of R<sup>2</sup> or R<sup>3</sup> is selected from the group consisting of:

(a) an optionally substituted alkyl group, preferably C<sub>1</sub>-C<sub>6</sub> alkyl, more preferably C<sub>1</sub>-C<sub>3</sub>;

30

(b) alkoxy, aryloxy, alkylthio or arylthio, any of which is optionally substituted;